WMIF MAIN SITE

2024 Event Site

The Inflation Reduction Act, What’s Next? At the World Medical Innovation Forum

Biopharmaceuticals and The Inflation Reduction Act: A Status Report on IRA Implementation
Pictured left to right, Tom Hubbard, Senior Vice President of the Network for Excellence in Health Innovation (NEHI), Peter Neumann, ScD, Director, Center for the Evaluation of Value and Risk in Health, Tufts Medical School and Steve Pearson, MD, President, ICER

The Inflation Reduction Act (IRA) of 2022 will impose some of the most far-reaching changes in federal policy on biopharmaceuticals in recent years, including direct negotiation of drug prices by Medicare, and a significant redesign of Medicare prescription drug benefits to lower costs borne by Medicare beneficiaries. This panel, among the most popular at the Forum, examines the ongoing implementation of key IRA provisions that may influence biopharmaceutical innovation in the years ahead. At the World Medical Innovation Forum this past June, our panels of experts in the field met to discuss the possible outcomes of this new policy.

Watch the session, Biopharmaceuticals and The Inflation Reduction Act: A Status Report on IRA Implementation presented at the World Medical Innovation Forum 2023.

The Inflation Reduction Act: The Emerging Implications for Biopharmaceutical Innovation
Later in the day, (pictured left to right) Hubbard led the second panel discussion alongside, Stephen Brady, CEO, Tempest Therapeutics, Remy Brim, PhD, Health and Life Sciences Practice Co-Head, BGR Group, Pat Fortune, PhD, Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation and John Lepore, MD, Senior Vice President, Head of Research, GSK.

Watch the session, The Inflation Reduction Act: The Emerging Implications for Biopharmaceutical Innovation from this year’s World Medical Innovation Forum.

© 2024 Mass General Brigham Incorporated. All Rights Reserved